We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nucleic Acid Extracted from Clinical, Research, and Environmental Samples

By LabMedica International staff writers
Posted on 04 Jul 2012
A rapidly growing biotechnology company has introduced a new kit for extracting nucleic acids from clinical, research, and environmental samples. More...


The new E-Sphere Simple NA Kit was developed by Phthisis Diagnostics (Charlottesville, VA, USA). The E-Sphere Simple NA Kit is the first total nucleic acid extraction product in Phthisis Diagnostics’ Simply Molecular product line.

It develops enzyme-based extraction kits for rapid sample preparation prior to polymerase chain reaction (PCR) applications in laboratories. The kit’s optimized workflow minimizes procedural steps, sample transfers, and potential for error.

The novel E-Sphere method allows manual DNA/RNA extraction from 12 samples in less than 30 minutes total time–from sample to PCR. This streamlined process includes only 4 steps and minimizes contamination risk with only 1 to 2 sample transfers. Samples can be quickly processed within a biological safety cabinet.

Advanced technology in the kit includes the high performance E-Sphere enzyme, a thermostable reagent that digests the sample at 75 °C during 15-minute incubation. A further innovation is the proprietary E-Sphere Clean-up Column, which purifies the DNA/RNA for downstream analysis.

Laboratories have expressed their need for a faster, simpler method to purify DNA/RNA from difficult sample types prior to PCR amplification and analysis. This new kit answers the market need for speed among manual extraction methods and provides the added benefits of accuracy, improved cost effectiveness, reduced risk of sample contamination, and greater safety for lab technicians. The process requires only standard clinical laboratory equipment.

The new product is part of the developing Simply Molecular product catalog, a range of molecular diagnostic products designed for speed, accuracy, and ease of use that offer solutions for nucleic acid extraction, molecular diagnostics, and laboratory quality control.

Upcoming products will include molecular diagnostics for parasites and fungi, as well as molecular standards for improved laboratory quality control. Phthisis Diagnostics is also developing molecular diagnostic assays using polymerase chain reaction (PCR) technology to detect infectious diseases, including Cryptosporidium, Giardia, Microsporidia, and others.

Related Links:
Phthisis Diagnostics



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.